David J Yvars Group Has $212,000 Stake in Pfizer Inc. (NYSE:PFE)

David J Yvars Group reduced its stake in Pfizer Inc. (NYSE:PFE) by 8.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,348 shares of the biopharmaceutical company’s stock after selling 742 shares during the period. David J Yvars Group’s holdings in Pfizer were worth $212,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in the stock. Norges Bank acquired a new stake in shares of Pfizer during the fourth quarter valued at about $2,328,986,000. Charles Schwab Investment Management Inc. increased its stake in shares of Pfizer by 19.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after buying an additional 25,315,159 shares during the period. Starboard Value LP bought a new position in Pfizer in the 4th quarter valued at approximately $407,730,000. Raymond James Financial Inc. acquired a new stake in Pfizer during the 4th quarter worth approximately $274,694,000. Finally, Assenagon Asset Management S.A. grew its holdings in Pfizer by 307.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company’s stock worth $254,574,000 after acquiring an additional 7,581,030 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of PFE stock opened at $24.51 on Friday. The firm has a 50 day moving average of $23.06 and a 200-day moving average of $24.95. The company has a market cap of $139.35 billion, a price-to-earnings ratio of 17.38, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same period last year, the company posted $0.82 earnings per share. The business’s quarterly revenue was down 7.8% on a year-over-year basis. On average, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 13th. Stockholders of record on Friday, May 9th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.02%. Pfizer’s dividend payout ratio is 124.64%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on PFE shares. UBS Group raised their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Cantor Fitzgerald assumed coverage on Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price target on the stock. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.